Sharesource Connectivity Platform for Use with Homechoice Claria Product Code 5CGM01 software...
FDA Device Recall #Z-0409-2026 — Class II — August 28, 2025
Recall Summary
| Recall Number | Z-0409-2026 |
| Classification | Class II — Moderate risk |
| Date Initiated | August 28, 2025 |
| Status | Ongoing |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Vantive US Healthcare LLC |
| Location | Deerfield, IL |
| Product Type | Devices |
| Quantity | 1 |
Product Description
Sharesource Connectivity Platform for Use with Homechoice Claria Product Code 5CGM01 software versions 7.13.3 (China), 8.13.2 (APAC and Korea), and 8.13.4 (US, EMEA, and LATAM)
Reason for Recall
Vantive has identified a software defect within the Sharesource Claria software, which may cause a patient s updated prescription program settings to not be properly saved on the actual cycler that the patient is using to perform their therapy. As a result, the clinician may think that the patient is receiving the correct prescribed therapy because of what is erroneously displayed on the clinician's remote Sharesource application, when in fact the cycler that is with the patient is actually delivering an outdated and incorrect therapy.
Distribution Pattern
Worldwide distribution - US Nationwide and the countries of Australia, Hong Kong, Korea, New Zealand, Taiwan, Thailand, France, Germany, Ireland, Netherlands, Italy, Spain, Turkey, United Kingdom, Chile, and Colombia.
Lot / Code Information
UDI-DI 15413765545723 software versions 7.13.3 (China), 8.13.2 (APAC and Korea), and 8.13.4 (US, EMEA, and LATAM)
Other Recalls from Vantive US Healthcare LLC
| Recall # | Classification | Product | Date |
|---|---|---|---|
| Z-1227-2026 | Class II | PRIMSAFLEX M100 SET, Product Code 106697; Dialy... | Jan 6, 2026 |
| Z-1224-2026 | Class II | PRISMAFLEX ST100 SET US, Product Code 107636US;... | Jan 6, 2026 |
| Z-1226-2026 | Class II | OXIRIS SET, Product Code 112016; Dialyzer, High... | Jan 6, 2026 |
| Z-1228-2026 | Class II | PRISMAFLEX M150 SET, Product Code 109990; Dialy... | Jan 6, 2026 |
| Z-1231-2026 | Class II | PRISMAFLEX TPE2000 SET, Product Code 114093; Di... | Jan 6, 2026 |
Frequently Asked Questions
A software recall means the device's embedded software or firmware has a defect that could affect its performance or safety. Many software recalls are corrected through firmware updates that can be applied without physically replacing the device. For implantable devices, the update may be delivered wirelessly during a routine clinic visit. For external devices, the manufacturer may provide updated software files or replacement units. Contact your healthcare provider to determine whether your specific device and software version are affected and what action is recommended.
Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.
Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.
What Should You Do?
Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.